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Recently, the first Neisseria gonorrhoeae strain (H041) highly resistant to the expanded-spectrum cephalosporins (ESCs) ceftri-
axone and cefixime, which are the last remaining options for first-line gonorrhea treatment, was isolated in Japan. Here, we con-
firm and characterize a second strain (F89) with high-level cefixime and ceftriaxone resistance which was isolated in France and
most likely caused a treatment failure with cefixime. F89 was examined using six species-confirmatory tests, antibiograms (33
antimicrobials), porB sequencing, N. gonorrhoeae multiantigen sequence typing (NG-MAST), multilocus sequence typing
(MLST), and sequencing of known gonococcal resistance determinants (penA, mtrR, penB, ponA, and pilQ). F89 was assigned to
MLST sequence type 1901 (ST1901) and NG-MAST ST1407, which is a successful gonococcal clone that has spread globally. F89
has high-level resistance to cefixime (MIC  4 g/ml) and ceftriaxone (MIC  1 to 2 g/ml) and resistance to most other antimi-
crobials examined. A novel penA mosaic allele (penA-CI), which was penA-XXXIV with an additional A501P alteration in
penicillin-binding protein 2, was the primary determinant for high-level ESC resistance, as determined by transformation into a
set of recipient strains. N. gonorrhoeae appears to be emerging as a superbug, and in certain circumstances and settings, gonor-
rhea may become untreatable. Investigations of the biological fitness and enhanced understanding and monitoring of the ESC-
resistant clones and their international transmission are required. Enhanced disease control activities, antimicrobial resistance
control and surveillance worldwide, and public health response plans for global (and national) perspectives are also crucial. Nev-
ertheless, new treatment strategies and/or drugs and, ideally, a vaccine are essential to develop for efficacious gonorrhea
management.
Gonorrhea is the second most prevalent bacterial sexuallytransmitted infection worldwide. The etiological agent of
gonorrhea, Neisseria gonorrhoeae, has developed antimicrobial re-
sistance (AMR) to all previous first-line drugs, e.g., penicillins,
tetracycline, and fluoroquinolones (3, 18, 20, 39, 41), leaving the
expanded-spectrum cephalosporins (ESCs) ceftriaxone and cef-
ixime as the only antibiotics recommended for treatment of
gonococcal infections. Unfortunately, during the past decade, sus-
ceptibility to ESCs has decreased globally (3, 5, 18, 20, 41). Treat-
ment failures with cefixime have been verified in Japan (10, 41, 55)
for many years, but recently, treatment failures have also been
reported in Norway (46), Austria (45), and the United Kingdom
(16). It appears that a few very successful gonococcal lineages
(clones), e.g., the multilocus sequence typing (MLST) sequence
type 7363 (ST7363) and ST1901, which most likely originated in
Japan, are spreading globally and account for a substantial pro-
portion of the isolates showing decreased susceptibility and resis-
tance to ESCs and multidrug resistance in many countries (12, 15,
23, 29, 38, 42, 53; http://pubmlst.org/neisseria/; M. Ohnishi and
M. Unemo, unpublished data). The recent gonorrhea treatment
failures with cefixime in Norway (46), Austria (45), and the
United Kingdom (16) were caused by the MLST ST1901 clone,
which appears to have evolved into multiple different N. gonor-
rhoeae multiantigen sequence typing (NG-MAST) STs. Of these,
NG-MAST ST1407 is the most prevalent in Europe and has been
spreading worldwide (8, 12, 15, 16, 33, 38, 42, 45, 46; http://www
.ng-mast.net; Ohnishi and Unemo, unpublished). Recently, the
first extensively drug-resistant (XDR) (41) gonococcal strain
(H041) was isolated in Japan and characterized (27, 28). H041 has
high-level resistance to both cefixime (MIC  8 g/ml) and ceftri-
axone (the last remaining option for empirical first-line treat-
ment; MIC  2 to 4 g/ml) and was most likely related to a clinical
failure using ceftriaxone at 1 g intravenously. This strain was as-
signed to MLST ST7363 (NG-MAST ST4220). High-level resis-
tance to all ESCs was due primarily to a novel penA mosaic allele
(27). If these ESC-resistant strains start to spread globally, gonor-
rhea will become untreatable in certain circumstances and espe-
cially in some settings (27, 41). Thus, it is crucial to investigate in
detail all gonococcal strains suspected to be resistant to the rec-
ommended ESCs using quality-assured methods in order to con-
firm resistance, predict the possibility of treatment failure and
further spread of the strains, and elucidate their phenotypic and
genetic characteristics, in particular, their resistance mechanisms.
The main mechanism in N. gonorrhoeae for decreased suscep-
tibility and resistance to ESCs is alteration of the penA gene, en-
coding penicillin-binding protein 2 (PBP 2), which is the lethal
target for these antimicrobials. Decreased susceptibility may be
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due to acquisition of a penA mosaic allele or alterations of A501 or
possibly G545 and P551 in the transpeptidase/-lactam binding
domain of PBP 2 (1, 2, 3, 12, 15–21, 24, 27–29, 32, 33, 36–38,
41–43, 45, 46, 48, 51–54, 58). Mutations in the promoter and/or
coding sequence of mtrR result in the overexpression of the MtrC-
MtrD-MtrE efflux pump, which further decreases ESC suscepti-
bility (1, 3, 12, 13, 19–21, 27, 35, 41, 43, 45, 46, 48, 50, 56, 58), and
porB1b mutations that alter amino acids G101 and A102 in the
PorB1b porin (the penB resistance determinant) result in addi-
tionally decreased ESC susceptibilities, especially for the injectable
ceftriaxone (1, 3, 12, 19–21, 27, 30, 31, 35, 41, 43, 45, 46, 48, 58).
Mutations in ponA (encoding PBP 1) and pilQ (encoding the
pore-forming secretin PilQ protein in the type IV pili), which can
be involved in high-level penicillin resistance, do not substantially
enhance the MICs of ESCs in the currently circulating gonococcal
strains (12, 27, 34, 54, 57, 58). At least one nontransformable
resistance determinant remains unknown (12, 21, 27, 34, 43, 58).
The aims of the present study were to report the isolation,
verification, and characterization of a second N. gonorrhoeae
strain found worldwide (identified in France) with high-level
cefixime and ceftriaxone resistance, which was most likely related
to a treatment failure with cefixime. Thus, the present study de-
scribes the detailed phenotypic and genetic characterization of
this strain, including molecular epidemiological characteristics
and elucidation of the resistance mechanisms causing the high-
level ESC resistance.
MATERIALS AND METHODS
Gonorrhea patient and case management. The high-level cefixime- and
ceftriaxone-resistant strain 10240089 (referred to here as F89) was iso-
lated at test of cure from a urethral specimen from a 50-year-old man who
had sex with men (MSM) in June 2010 in Quimper, France. The patient
had been administered cefixime at 200 mg per os, two doses (6 hours
apart), 3 weeks earlier due to a diagnosis of culture-positive symptomatic
gonorrhea (urethral discharge and dysuria); the patient repeatedly denied
any sexual activity between the time of treatment and the test of cure. The
patient did not have any recent travels abroad and was therefore infected
in France; however, the sexual contact was not possible to trace. The
patient was then successfully treated with gentamicin at 160 mg intramus-
cularly, single dose, which was verified by culture negativity 3 weeks later.
Species verification of high-level cefixime- and ceftriaxone-resistant
Neisseria gonorrhoeae strain F89. F89 was grown as previously described
(49) and verified to be N. gonorrhoeae using six species-confirmatory tests:
(i) sugar utilization, (ii) PhadeBact GC monoclonal test (Bactus AB,
Solna, Sweden), (iii) PhadeBact GC monoclonal serovar test (Bactus AB,
Solna, Sweden), (iv) MicroTrak N. gonorrhoeae culture confirmation test
(Trinity Biotech, Wicklow, Ireland), (v) porA pseudogene PCR (14), and
(vi) dual-target PCR (porA and opa) (11).
Antimicrobial susceptibility testing. MICs of ceftriaxone, cefixime,
and 31 additional antimicrobials for F89 were determined using the Etest
method (AB bioMérieux, Solna, Sweden) according to the manufacturer’s
instructions. The MIC of ceftriaxone was also determined using the agar
dilution method according to the standards from the Clinical and Labo-
ratory Standards Institute (CLSI) (9). The susceptibility to five antimicro-
bials (penicillin G, cefpodoxime, ceftriaxone, ciprofloxacin, and spectino-
mycin) was also determined using the calibrated dichotomous sensitivity
(CDS) disc diffusion method (40; http://web.med.unsw.edu.au/cdstest,
accessed 20 November 2011), which is used in resistance surveillance of N.
gonorrhoeae in many countries in the World Health Organization (WHO)
Western Pacific Region (WPR) (Table 1). -Lactamase production was
tested using nitrocefin discs. The 2008 WHO N. gonorrhoeae reference
strains (48) were used as quality controls in all antimicrobial susceptibility
testing.
TABLE 1 Susceptibilities of high-level cefixime- and ceftriaxone-
resistant N. gonorrhoeae strain F89 to various antimicrobials
Class, subclass, and antimicrobial
MIC Etesta










-Lactams, monobactams, aztreonam 64 ND
-Lactams, cephalosporins
Cefuroxime 16 (R)b ND
Cefpodoxime 16 (R)b 6 (R)
Ceftazidime 16 (R)b ND
Cefotaxime 4 (R)b,c ND
Cefixime 4 (R)b,c ND
Ceftriaxone 2 (1)a (R)b,c 3 (R)
















Aminocyclitol, spectinomycin 16 (S)b,c 13 (S)
Tetracyclines, tetracycline 2 (R)c ND




Rifamycins, rifampin 0.5 ND
Chloramphenicol 4 ND
Nitrofurantoin 1 ND
Fusidic acid 2 ND
a MICs were determined using the Etest method (AB bioMérieux, Solna, Sweden) according
to the instructions from the manufacturer. Agar dilution was additionally performed for
ceftriaxone (the result is in parentheses) according to the method described by the Clinical
Laboratory and Standards Institute (CLSI) (9). The Etest method is capable of providing
half-MIC steps; however, in accordance with the interpretation of the agar dilution method
described by the CLSI (9), only whole-MIC steps are given.
b Where available, interpretative criteria (S, susceptible; I, intermediate susceptible; R,
resistant) from the CLSI (9) were used.
c Interpretative criteria (susceptible, intermediate susceptible, resistant) from the
European Committee on Antimicrobial Susceptibility Testing (EUCAST; available
online at www.eucast.org/Clinical breakpoints [accessed 20 November 2011]) are also
reported where available.
d The calibrated dichotomous sensitivity (CDS) disc diffusion method (40; http://web
.med.unsw.edu.au/cdstest) is used for antimicrobial resistance testing in many coun-
tries in the World Health Organization (WHO) Western Pacific Region.
e ND, not determined.
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DNA extraction. DNA was isolated in a NorDiag Bullet instrument
(NorDiag ASA Company, Oslo, Norway) using a BUGS’n BEADS STI-fast
kit (NorDiag ASA Company, Oslo, Norway) according to the manufac-
turer’s instructions.
Genetic characterization. Molecular epidemiological characteriza-
tion of F89 by means of MLST (29), porB gene sequencing, and NG-MAST
(44) was performed as described previously. PCR amplification and se-
quencing of known gonococcal resistance determinants, i.e., penA, mtrR,
porB1b, ponA, and pilQ, were done as described elsewhere (21, 48, 54).
Sequence alignments and phylogenetic analysis. Multiple-sequence
alignments were performed using the Bioedit sequence alignment editor
software (version 7.0.9.0). The evolutionary relationship of F89 to other
penA mosaic strains displaying decreased ESC susceptibility and resis-
tance (12, 27) was examined using a phylogenetic analysis of the full-
length porB sequences with the TREECON program (version 1.3b) as
previously described (44).
Transformation assays. Transformation experiments (three repli-
cates), using purified PCR-amplified full-length penA, to verify that the
novel penA mosaic allele was the causative determinant of high-level
cefixime and ceftriaxone resistance in F89, were performed using one
clinical strain and four of the eight 2008 WHO N. gonorrhoeae reference
strains (48) as recipients as previously described (27, 29). The recipient
strains displayed different molecular epidemiological STs, cefixime MICs,
ceftriaxone MICs, and compositions of ESC resistance mechanisms, such
as penA alleles, the mtrR promoter mutation, and penB sequences (Table
2). The full-length penA allele, as well as the other known gonococcal
resistance determinants, i.e., the mtrR, porB1b, ponA, and pilQ genes, were
sequenced in all transformants.
Nucleotide sequence accession number. The GenBank/EMBL/DDBJ
accession number for the new penA allele of F89 (referred to as penA-CI;
see text below) is JQ073701.
RESULTS
Phenotypic characterization of the high-level cefixime- and
ceftriaxone-resistant Neisseria gonorrhoeae strain F89. All con-
ventional bacteriological tests and six species-verifying assays (see
Materials and Methods) confirmed that F89 is a gonococcal strain.
The serovar determination assigned F89 to serovar Bpyut.
The results of antimicrobial susceptibility testing of F89 are
summarized in Table 1. Briefly, F89 displayed high-level resistance
to cefixime (MIC  4 g/ml; actually, 3 g/ml according to the
Etest method), ceftriaxone (MIC  1 g/ml [agar dilution] to 2
g/ml [Etest, 1.5 g/ml]), and all additional ESCs tested. F89 was
also resistant to most of the antimicrobials previously used for
treatment of gonorrhea, including all fluoroquinolones, macro-
lides, tetracycline, trimethoprim-sulfamethoxazole, and chloram-
phenicol. Regarding other -lactam antimicrobials, the MICs of
penicillin G, ampicillin, and piperacillin, as well as the carbapen-
ems ertapenem and meropenem, were surprisingly low (Table 1).
The strain did not produce any -lactamase. Finally, F89 was sus-
ceptible to spectinomycin, and the MICs of aminoglycosides, tige-
cycline, and rifampin were relatively low (as for ampicillin, pip-
eracillin, and carbapenems, no breakpoints are available for these
antimicrobials) (Table 1).
Molecular epidemiological characterization of the high-
level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae
strain F89. Molecular epidemiological characterization of F89 as-
signed it to MLST ST1901 and NG-MAST ST1407. Phylogenetic
analysis of full-length porB sequences showed that F89 is identical
to previously examined penA mosaic ST1407 isolates (12, 27),
which display decreased susceptibility and resistance to ESCs and
have been cultured worldwide (data not shown).
Elucidation of the genetic resistance mechanisms causing the
high-level cefixime and ceftriaxone resistance in F89. The se-
quencing of ESC resistance determinants showed that the strain
contained a novel penA mosaic allele, i.e., a PBP 2 XXXIV mosaic
allele (27, 33) with a single additional transversion (G ¡ C in bp
1501 in penA), resulting in a A501P alteration in PBP 2 (Fig. 1),
which to our knowledge has not been previously described in N.
gonorrhoeae or in other Neisseria species. In Fig. 1, the penA alleles
of H041 (27) and F89 have been designated C and CI, respectively,
in accordance with the PBP 2 sequences and nomenclature pro-
posed by Ohnishi et al. (27). Substantially higher numbers for the
alleles were used to prevent confusion with the numbering of penA
alleles reported by Allen et al. (1), some of which differ from the
numbers used in the numbering system described by Ohnishi et al.
(27). F89 also contained two previously verified ESC resistance
determinants: (i) mtrR (an A deletion in the inverted repeat in the
promoter, which increases expression of the MtrC-MtrD-MtrE
TABLE 2 Neisseria gonorrhoeae strains with different cefixime MICs and ceftriaxone MICs and containing different resistance determinants used as
recipients in transformation experiments of full-length penA gene from F89
Strain MLST STa NG-MAST STb
MIC (g/ml)c Genotype
Cefixime Ceftriaxone penAd mtrRe penBf ponAg
WHO F New ST3303 0.016e 0.002e penA XV (WT) WTh WT WT
WHO M ST7367 ST3304 0.016 0.016e penA II (A345a) A-del Yes L421P
WHO K ST7363 ST1424 0.5 0.064 penA X (Mosaic) A-del Yes L421P
35/02 ST7363 ST326 0.5 0.125 penA XXVIII (Mosaic) A-del Yes L421P
WHO L ST1590 ST1422 0.25 0.125 penA VII (A501V) A-del Yes L421P
a MLST, multilocus sequencing typing (29).
b NG-MAST, Neisseria gonorrhoeae multiantigen sequence typing (44).
c The Etest method reads also half-MIC steps; however, in accordance with the interpretation of the agar dilution method described by the Clinical Laboratory and Standards
Institute (CLSI) (9), only whole-MIC steps are given. MICs of 0.002 g/ml and 0.016 g/ml were calculated as 0.001 g/ml and 0.008 g/ml, respectively, in the MIC ratios in
Fig. 2.
d penA mosaic allele encodes a mosaic penicillin-binding protein 2 (PBP 2) that causes a decreased susceptibility to extended-spectrum cephalosporins (ESCs) (21, 27, 36, 41, 43, 58).
e A-del, a characteristic single-nucleotide (A) deletion in the inverted repeat of the promoter region of mtrR that causes overexpression of the MtrCDE efflux pump, resulting in a
further decreased susceptibility to ESCs (21, 27, 41, 58).
f Yes, the presence of the alterations of amino acids 101 and 102 in porin PorB (penB determinant) that cause a decreased intake of ESCs and, accordingly, a further decreased
susceptibility to ESCs (21, 27, 41, 58).
g The alteration of amino acid 421 in PBP 1 (encoded by ponA) causes decreased susceptibility to penicillins (21, 34, 58).
h WT, wild type.
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efflux pump) and (ii) penB (porB1b containing G101K and A102N
alterations, which decrease diffusion of antimicrobials into the
periplasm). It also contained penicillin resistance determinants
such as the ponA1 alteration (L421P), which encodes an altered
form of PBP 1, and a pilQ VII allele (54). Accordingly, F89 was
nearly identical to the previously described ST1407 strain causing
treatment failures in Norway (46), with the novel penA-CI allele
being the only new resistance determinant. Consequently, this
allele was suspected to be the primary determinant responsible for
the high MICs of ESCs.
To ascertain whether the increased resistance to ESCs was due
to the novel penA-CI allele, the full-length penA-CI allele from F89
was amplified and used to transform four WHO reference strains
and one clinical isolate, and the MICs of ceftriaxone and cefixime
for the resulting sequence-verified transformants were deter-
mined. The experiments confirmed that penA-CI conferred high-
level resistance to both cefixime and ceftriaxone (Fig. 2). Trans-
formation of penA-CI into the recipient strains increased the
MICs of cefixime between 8- and 500-fold (MICs  2 to 8 g/ml;
actually, 1.5 to 6.0 g/ml according to the Etest method) and of
ceftriaxone from 31- to 500-fold (MICs  0.5 to 4 g/ml; actually,
0.34 to 3.3 g/ml according to the Etest method), which were
above the resistance breakpoints (0.25 g/ml) for both antimi-
crobials (9). Remarkably, transformants of WHO F, which has
wild-type alleles of all known ESC and penicillin resistance deter-
minants, displayed mean MICs of cefixime and ceftriaxone of 2
g/ml (1.5 g/ml, according to the Etest method) and 0.5 g/ml
(0.34 g/ml, according to the Etest method), respectively, which
represents an increase of 500-fold for the MICs of both ESCs
(Fig. 2).
All transformants contained the penA-CI allele and had mtrR,
penB, and ponA sequences identical to those from their respective
parental strain. In all transformants except strain 35/02, the trans-
formed penA-CI sequence was identical to that from F89. In strain
35/02, a few single nucleotide polymorphisms (SNPs) and one
inserted codon of 3 bp in the C-terminal end of the penA gene
(after bp 1647) differed from the penA-CI sequence, but most of
these SNPs were synonymous and this segment of the mosaic penA
allele most likely does not affect the MICs of cefixime or ceftriax-
one. Consequently, these transformation experiments confirmed
that the novel penA-CI mosaic allele is responsible for high-level
cefixime and ceftriaxone resistance, although the MICs of the
ESCs for the recipient strains vary depending on whether they
contain additional resistance determinants (e.g., mtrR and penB).
DISCUSSION
This study reports the detailed phenotypic and genetic character-
ization and resistance mechanism of the high-level cefixime and
ceftriaxone resistance in strain F89, the second N. gonorrhoeae
strain showing high-level resistance to ESCs worldwide. F89 was
FIG 1 Alignment of PBP 2 sequences from strains of Neisseria gonorrhoeae with different penA alleles. M32091, wild-type PBP 2; XXXIV, penA mosaic allele
previously described (27, 33); CI, penA mosaic allele of F89; XXVI (27, 36) and XXX (27, 51), the only previously reported true penA mosaic alleles containing
an A501 alteration (27); C, penA mosaic allele of H041, which is the first high-level ceftriaxone-resistant strain found in Japan (27); and XIII and XVIII, previously
described nonmosaic penA alleles that contain A501V (most prevalent) and A501T alterations (27, 51). Identical amino acids are designated by a dot, and
alterations from the wild-type sequence are shown with a single capital letter. The three active-site motifs are marked by dashed boxes, while the location of amino
acid Ala501 (position 502 in the alignment due to the D345 insertion) is marked with a solid box.
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isolated from an MSM in Quimper, France, and most likely was
related to a treatment failure with cefixime. Previously, only one
other strain (H041 isolated in Japan), which belongs to the inter-
nationally spreading MLST ST7363, has shown high-level resis-
tance to cefixime and ceftriaxone (27, 28). It is of grave concern
that another N. gonorrhoeae strain, F89, which belongs to an ad-
ditional international successful clone (MLST ST1901, with
ST1407 being the most prevalent NG-MAST ST in Europe), has
FIG 2 MICs of a set of recipient strains transformed with the full-length penA allele (penA-CI) from the high-level cefixime- and ceftriaxone-resistant Neisseria
gonorrhoeae strain F89 (donor). The MICs of cefixime and ceftriaxone and the number and type of resistance determinants (e.g., mtrR, penB, and ponA) in the recipient
strains varied. The MICs of cefixime (A) and ceftriaxone (B) were determined using the Etest method, and the values shown are the means of three transformation experiments
(the bars give only whole-MIC steps), with the exact mean MICs in parentheses. The ratios of the MICs of the transformant to the recipient strain (T/R) are indicated.
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also developed high-level resistance to both cefixime and ceftriax-
one, the last options for first-line treatment of gonorrhea. The
gonococcus appears to have evolved into a superbug that may
initiate a future era of untreatable gonorrhea.
Although a pretreatment isolate was not available to defini-
tively confirm treatment failure with cefixime, it appears most
likely for a number of reasons: (i) lack of sexual activity between
treatment and test of cure, (ii) the very high MIC of cefixime for
F89, and (iii) all pharmacokinetic and pharmacodynamic data for
cefixime. According to simulations, the treatment regimen used
(cefixime 200 mg per os, two doses, 6 h apart) results in median
times of free cefixime concentration above the MIC (fTMIC) of 0
h for a strain, i.e., F89, with a cefixime MIC of 4 g/ml (6). Thus,
using this dosage regimen for treatment of gonorrhea caused by
F89 is highly unlikely to clear the infection.
Transformation experiments with several recipient strains
demonstrated that the novel penA-CI mosaic allele in F89 is the
primary determinant for resistance to cefixime and ceftriaxone.
Transfer of penA-CI into even a wild-type strain with no known
resistance determinants resulted in MICs above the resistance
breakpoints for both antibiotics; however, additional resistance
determinants, especially mtrR and penB, were required to reach
the same (or even higher) MICs of cefixime and ceftriaxone as the
donor strain. The synergy between penA, mtrR, and penB has been
previously reported (21, 27, 41, 58), although the synergistic effect
is much more pronounced for ceftriaxone than for cefixime (58).
Notably, WHO L displayed substantially higher cefixime and
ceftriaxone MICs than the other recipient strains after transfor-
mation (Fig. 2). Thus, WHO L may harbor factor X, i.e., the non-
transformable determinant that remains to be identified (12, 21,
27, 34, 43, 58), and it cannot be excluded that the cefixime and
ceftriaxone MICs are also enhanced by the mtr120 mutation in
WHO L (26).
The penA-CI sequence is nearly identical to the penA-XXXIV
mosaic allele (27), with penA-CI containing only a single addi-
tional transversion (G1501C) that results in an A501P alteration
in PBP 2. The penA-XXXIV mosaic allele was initially described in
2008 in an NG-MAST ST1407 isolate in San Francisco (33) and
recently reported in Taiwan (15) and Canada (1). Whereas these
strains had cefixime and ceftriaxone MICs of 0.125 to 0.25 g/ml
and 0.06 to 0.125 g/ml, respectively (1, 15, 33), F89 had markedly
higher MICs of cefixime and ceftriaxone (4 g/ml and 1 to 2
g/ml, respectively). Although the structure of PBP 2 with an
A501P, A501V, or A501T mutation has not been reported, it has
been suggested that replacement of the methyl side chain of
Ala501, which is located on the 3-4 loop very close to the KTG
active-site motif of PBP 2 (Fig. 1) (43), with the more bulky side
chains of valine or threonine inhibits the binding of cefixime and
ceftriaxone to PBP 2 by clashing with their R1 substituents. The
change of Ala501 to a proline introduces secondary structure al-
terations that may result in changes even more dramatic than
those obtained with valine and threonine, and this is consistent
with the much higher MICs conferred by the A501P mutation
than the other mutations. In regard to other -lactams, the less
bulky R1 substituent of penicillin G, ampicillin, and the carba-
penems may explain why they were less affected by the A501P
alteration; indeed, it was shown previously that the MIC of peni-
cillin actually decreased in strains harboring a penA-X A501V al-
lele compared to the same strain with the penA-X allele (43). In
contrast, the reason for the low MIC of piperacillin, which also
contains a bulky R1 substituent, remains unknown (Table 1).
To our knowledge, the A501P alteration in PBP 2 has not been
previously reported in any strain of N. gonorrhoeae or other Neis-
seria species. In N. gonorrhoeae, Ala501 alterations (A501V and
A501T) have mostly been described in strains with nonmosaic
penA alleles, e.g., XIII (A501V) and XVIII (A501T) (27, 51), hav-
ing MICs of ceftriaxone of 0.06 to 0.125 g/ml (51). In fact, only
two mosaic penA sequences (XXVI [36] and XXX [29]), i.e., se-
quences containing amino acid alterations proven to decrease the
susceptibility to ESCs, e.g., in A311, I312, V316, N512, and G545
(27, 36, 43), that contain an Ala501 alteration (A501V in both of
these sequences) have been reported (Fig. 1) (27). The MICs of
cefixime were only 0.12 to 0.25 g/ml and 0.5 to 1.0 g/ml for
these strains, with the differences likely due to the presence or
absence of other resistance determinants, e.g., mtrR, penB, and/or
factor X. It has also been shown previously that transformation of
FA6140, a penicillin-resistant but cephalosporin-susceptible iso-
late containing all known resistance determinants, including fac-
tor X, with the mosaic penA-X allele harboring an additional
A501V alteration increases the MICs of both cefixime and ceftri-
axone to levels above their resistance breakpoints (43).
Alteration of Ala501 in PBP 2 may be gonococcus specific,
perhaps due to ESC selection pressure (12, 43, 53). Indeed, Taka-
hata et al. (36) reported the finding of a spontaneous A501V mu-
tation during transformation experiments with mosaic penA al-
leles. Moreover, isolates with nonmosaic penA alleles containing
Ala501 mutations have been assigned to many different MLST and
NG-MAST STs (12, 51, 53), which further supports the hypothesis
that spontaneous Ala501 mutations have arisen in many different
gonococcal clones due to ESC selective pressure. The rarity of
gonococcal strains containing a penA mosaic allele with an Ala501
alteration may suggest that these strains have a lower biological
fitness. The knowledge regarding the Ala501 alterations in mosaic
as well as in nonmosaic penA alleles is limited, and further research
is imperative. Finally, many different mosaic and nonmosaic penA
alleles altered at Ala501 (27) have emerged and continue to
emerge, and their effects on the MICs of ESCs of the correspond-
ing gonococcal isolates can vary markedly; e.g., some mosaic and
A501 altered alleles do not significantly increase the MICs of ESCs
(12, 19, 41, 42, 51, 52). Therefore, it is crucial to elucidate the
effects of all amino acid alterations suspected to enhance the MICs
of ESCs by transformation of site-directed penA mutants into iso-
genic strain backgrounds, i.e., show causality, and not just de-
scribe statistical associations between the presence of specific
amino acid alterations and elevated MICs of ESCs. It is also im-
portant to agree on the nomenclature of gonococcal penA alleles,
e.g., as proposed by Ohnishi et al. (27), including an internation-
ally accessible database, in order to avoid divergent numbering of
identical PBP 2 alleles.
F89 was assigned to MLST ST1901 (NG-MAST ST1407),
which likely originated in Japan and, along with MLST ST7363,
has been successful in spreading worldwide. The treatment fail-
ures with cefixime in Norway (46), Austria (45), and, likely, the
United Kingdom (16) were caused by the MLST ST1901 clone
(NG-MAST ST1407), even though the United Kingdom strains
belonged to NG-MAST ST3779 and ST3431. These NG-MAST
STs seem to have evolved from the closely related ST1407, which
all share the tbpB110 allele and differ in only one SNP each in the
porB908 allele. Although NG-MAST ST1407 appears to be the
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most prevalent NG-MAST ST of MLST ST1901 in Europe, many
NG-MAST STs of the MLST clone ST1901 have been identified
globally. In Japan, where the MLST ST1901 clone has been spread-
ing for at least 10 years, many related genetic variants of NG-
MAST ST1407, and possibly an additional NG-MAST clone(s)
assigned to MLST ST1901, have evolved (12, 15, 16, 23, 33, 42, 45,
46; http://www.ng-mast.net; Ohnishi and Unemo, unpublished).
F89 appears to represent a subclone of the MLST ST1901/NG-
MAST ST1407 clone that has developed high-level resistance to
cefixime and ceftriaxone. Thus, two successful N. gonorrhoeae
clones (MLST ST7363 and MLST ST1901) are spreading world-
wide and have shown their capacity to develop high-level resis-
tance to cefixime and ceftriaxone. If strains with high-level resis-
tance to cefixime and ceftriaxone start to spread globally, which
historically has been the scenario for spread of emerged gonococ-
cal resistance, gonorrhea might become untreatable. It is of great
concern that the first two N. gonorrhoeae strains with high-level
cefixime and ceftriaxone resistance have been identified in high-
risk frequently transmitting populations, i.e., the Japanese strain
H041 from a female commercial sex worker (27) and the French
strain F89 from an MSM. To date, the spread of these strains has
not been observed and additional treatment failures have not been
identified. This fact may be due to suboptimal surveillance of
gonococcal antimicrobial resistance and gonorrhea treatment
failures, but it cannot be excluded that the penA alleles that confer
high-level cefixime and ceftriaxone resistance cause a lower bio-
logical fitness that limits their further spread. Accordingly, the
biological fitness of these first strains with high-level cefixime and
ceftriaxone resistance is crucial to examine.
In conclusion, N. gonorrhoeae appears to be rapidly evolving
into a superbug, in which case future gonorrhea infections may
become untreatable. It is of great concern that two globally
spreading MLST clones (ST7363 and ST1901) have shown an abil-
ity to develop high-level resistance to cefixime and ceftriaxone,
and any future spread of these clones may need to be monitored
using appropriate molecular epidemiological typing (47). For
public health purposes, enhanced disease control activities,
quality-assured surveillance of AMR and treatment failures
worldwide, and public health action plans (global and national
perspectives) are crucial. These data also highlight the urgent need
for new treatment strategies, new antimicrobial agents, and, ide-
ally, a vaccine for effective treatment of gonorrhea (4, 6, 7, 22, 25,
27, 41, 45, 46, 48).
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